Advertisement

Journal of Neurology

, Volume 261, Issue 6, pp 1069–1072 | Cite as

Intravenous tenecteplase in acute ischemic stroke: an updated review

  • Réza Behrouz
Review

Abstract

Tenecteplase in a genetically engineered variant of alteplase. Although the two have the same mechanism of action, tenecteplase has properties that makes it a seemingly more advantageous thrombolytic. Because of its rapid single-bolus administration, its use is favored over alteplase in the treatment of acute myocardial infarction. Over the past few years, several clinical studies have been conducted to assess the safety, feasibility, and efficacy of tenecteplase in ischemic stroke. In spite of the mixed results of these studies, experimentation with tenecteplase continues in from of clinical trials. In this article, the utility of tenecteplase in ischemic stroke will be discussed.

Keywords

Stroke Cerebrovascular disease Tenecteplase Alteplase Tissue plasminogen activator Thrombolytics Thrombolysis Pharmacology 

Notes

Conflicts of interest

Dr. Behrouz has received educational grant from Genentech Inc. The author declares that he has no conflict of interest.

References

  1. 1.
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1588CrossRefGoogle Scholar
  2. 2.
    Bluhmki E, Chamorro A, Dávalos A et al (2009) Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 8:1095–1102CrossRefPubMedGoogle Scholar
  3. 3.
    The Ancrod Stroke Study Investigators (1994) Ancrod for the treatment of acute ischemic brain infarction. Stroke 25:1755–1759CrossRefGoogle Scholar
  4. 4.
    Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM, ESTAT Investigators (2006) Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 368:1871–1878CrossRefPubMedGoogle Scholar
  5. 5.
    Hacke W, Albers G, Al-Rawi Y et al (2005) The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-h window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36:66–73CrossRefPubMedGoogle Scholar
  6. 6.
    Davydov L, Cheng JW (2001) Tenecteplase: a review. Clin Ther 23:982–997CrossRefPubMedGoogle Scholar
  7. 7.
    Ross AM (1999) New plasminogen activators: a clinical review. Clin Cardiol 22:165–171CrossRefPubMedGoogle Scholar
  8. 8.
    Van De Werf F, Adgey J, Ardissino D et al (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354:716–722CrossRefGoogle Scholar
  9. 9.
    Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J (2001) Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 32:748–752CrossRefPubMedGoogle Scholar
  10. 10.
    Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM, TNK in Stroke Investigators (2005) A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 36:607–612CrossRefPubMedGoogle Scholar
  11. 11.
    Parsons MW, Miteff F, Bateman GA et al (2009) Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 72:915–921CrossRefPubMedGoogle Scholar
  12. 12.
    Haley EC Jr, Thompson JL, Grotta JC et al (2010) Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 41:707–711PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Molina CA (2011) Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke 42:S16–S19CrossRefPubMedGoogle Scholar
  14. 14.
    Parsons M, Spratt N, Bivard A et al (2012) A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 366:1099–1107CrossRefPubMedGoogle Scholar
  15. 15.
    González RG (2012) Tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 367:275–276CrossRefPubMedGoogle Scholar
  16. 16.
    ClinicalTrials.gov. TNK-tPA Evaluation for Minor Ischemic Stroke with Proven Occlusion (TEMPO-1). http://clinicaltrials.gov/ct2/show/NCT01654445?term=tenecteplase&rank=6
  17. 17.
    ClinicalTrials.gov. Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST). http://clinicaltrials.gov/ct2/show/NCT01472926?term=tenecteplase&rank=4
  18. 18.
    von Kummer R, Albers GW, Mori E, DIAS Steering Committees (2012) The desmoteplase in acute ischemic stroke (DIAS) clinical trial program. Int J Stroke 7:589–596CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Division of Cerebrovascular Diseases and Neurological Critical Care, Department of NeurologyThe Ohio State University College of MedicineColumbusUSA

Personalised recommendations